Canadian Government Awards Aspect $72.75M

A $72.75 million government funding has been given to Canadian biotech company Aspect Biosystems to further develop its exclusive bioprinting expertise.

The $200 million, multi-year initiative will enhance Aspect’s medical biomanufacturing capacity, full-stack tissue therapeutic platform, and bio-printed tissue therapeutic range. The financing comes from the state of British Columbia and Canada.

Bioprinted tissue therapies are created by Aspect with the intention of supplementing or replacing particular biological processes. The business claims that integrated tissues and accessible implants are among the answers provided through these implantable, allogeneic cell-based treatments.

Aspect CEO Tamer Mohamed commented: “This significant investment from the governments of Canada and BC sends a strong signal of support for building and integrating the capabilities needed to discover, develop, and clinically manufacture new medicines for people with serious diseases.”